Best match

Most recent

ACE-1831 is under clinical development by Acepodia and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for B-Cell Non-Hodgkin Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for ...

ACE-1831 by Acepodia for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

Pharmaceutical Technology

ACE-1702 is under clinical development by Acepodia and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

ACE-1702 by Acepodia for Solid Tumor: Likelihood of Approval

Get the most recent info and news about Acepodia on HackerNoon, where 10k+ technologists publish stories for 4M+ monthly readers.

Acepodia is developing innovative, highly effective cell therapies for cancer that are broadly accessible for patients.

Acepodia News on
HackerNoon and Around the Web

Winner for Best Startup in Vallejo, Us!

acepodia.com

31 employees

Since 2016

Articles Around the Web

Read More Tech Stories Related to #Acepodia